Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.57 |
| ▸ | MAG | P20916 | 6/20 | 0.52 |
| ▸ | SELP | P16109 | 3/20 | 0.50 |
| ▸ | SELL | P14151 | 2/20 | 0.50 |
| ▸ | SELE | P16581 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313946 | 0.98 | SIGLEC7 (0.57) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL29380203 | 0.98 | SIGLEC7 (0.57) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30649829 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30654338 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30651987 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30652374 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30651520 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30649917 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30650869 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE | |
| SCHEMBL30652757 | 0.96 | SIGLEC7 (0.55) | SIGLEC7MAGSELPSELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731764-A2 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | Sanegene Bio USA Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20250382616-A1 | SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF | SANEGENE BIO USA INC (US) | 2025-12-18 | — | — | US | claimed |
| US-20250027089-A1 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. | 2025-01-23 | — | — | US | claimed |
| WO-2024263915-A2 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. (US) | 2024-12-26 | — | — | WO | claimed |
| US-20240309383-A1 | SMALL INTERFERING RNA TARGETING HBV AND USES THEREOF | SANEGENE BIO USA INC. | 2024-09-19 | — | — | US | claimed |
| US-20240301421-A1 | SMALL INTERFERING RNA TARGETING C3 AND USES THEREOF | SANEGENE BIO USA INC. | 2024-09-12 | — | — | US | claimed |
| US-20240294916-A1 | SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF | SANEGENE BIO USA INC. | 2024-09-05 | — | — | US | claimed |
| WO-2024175111-A2 | SMALL INTERFERING RNA TARGETING HBV AND USES THEREOF | SUZHOU SANEGENE BIO INC. (CN) | 2024-08-29 | — | — | WO | claimed |
| US-20240002857-A1 | DOUBLE STRANDED RNA TARGETING 17-BETA HYDROXYSTEROIDDEHYDROGENASE 13 (HSD17B13) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. | 2024-01-04 | — | — | US | claimed |
| WO-2023220561-A1 | DOUBLE STRANDED RNA TARGETING 17-BETA HYDROXYSTEROIDDEHYDROGENASE 13 (HSD17B13) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-4731764-A2 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | Sanegene Bio USA Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4720298-A1 | TREATMENT OF FGG RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260021188-A1 | 1'-ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025264616-A1 | SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF | SANEGENE BIO USA INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250382616-A1 | SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF | SANEGENE BIO USA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20240002857-A1 | DOUBLE STRANDED RNA TARGETING 17-BETA HYDROXYSTEROIDDEHYDROGENASE 13 (HSD17B13) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023220561-A1 | DOUBLE STRANDED RNA TARGETING 17-BETA HYDROXYSTEROIDDEHYDROGENASE 13 (HSD17B13) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230138928-A1 | 1'-ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023014938-A1 | 1'-ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20220169790-A1 | CARBOHYDRATE LIGANDS THAT BIND TO ANTIBODIES AGAINST GLYCOEPITOPES OF GLYCOSPHINGOLIPIDS | UNIV BASEL (CH) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309383-A1 | SMALL INTERFERING RNA TARGETING HBV AND USES THEREOF | HAVCR2, SNRPE, CD2BP2 | SIGLEC7 304/4885MAG 2633/4885SELP 832/4885 |
| US-20260021188-A1 | 1'-ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | PARP1, NSUN2, PARP2 | SIGLEC7 2066/4885MAG 4647/4885SELP 658/4885 |
| US-20240301421-A1 | SMALL INTERFERING RNA TARGETING C3 AND USES THEREOF | C3AR1, C1QBP, C9 | SIGLEC7 200/4885MAG 2210/4885SELP 340/4885 |
| US-20250382616-A1 | SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF | CFB, CFTR, RNASE1 | SIGLEC7 3089/4885MAG 3699/4885SELP 2045/4885 |
| US-20250027089-A1 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | SIGLEC7 1601/4885MAG 4189/4885SELP 963/4885 |
| US-20230138928-A1 | 1'-ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | PARP1, PARP2, PARP11 | SIGLEC7 943/4885MAG 3416/4885SELP 1957/4885 |
| US-20220169790-A1 | CARBOHYDRATE LIGANDS THAT BIND TO ANTIBODIES AGAINST GLYCOEPITOPES OF GLYCOSPHINGOLIPIDS | SIGLEC7, GALC, GBA1 | SIGLEC7 1/4885MAG 8/4885SELP 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.